Boston Pharmaceuticals was launched in late 2015 as a new pharmaceutical company model, providing a bridge to value realization for early stage clinical development programs. We are funded by Gurnet Point Capital, a $2 billion healthcare private equity fund, and are actively investing a significant long-term base of capital to build a carefully constructed portfolio of clinical candidates across a broad array of mechanisms and therapeutic targets.
Our internal team now stands at 16 employees, with a combined 250 years of pharmaceutical industry experience. Our team of pharmaceutical and biotechnology experts have successfully developed and evaluated hundreds of drug candidates across all development stages during their careers. We have direct clinical development experience in immunology, oncology, neurology, rare disease and infectious disease programs and our commercialization experience spans these areas and more.